I think this is a very important slide from the last trial results presentation, showing that control patients who received dexamethasone showed no survival benefit. But once treated with Remestemcel-L + dexamethasone, a significant survival benefit of 75% at day 60 and 77% at day 90 was observed (in patients<65).
No treatment for ARDS has ever shown such a significant mortality reduction in any patient population. These are the sickest Covid-19 patients who are in ICU on mechanical ventilation who now have an 86% chance of survival compared to just 55% with current SOC.
Ann: Appendix 4C Quarterly Activity Report, page-216
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.020(1.34%) |
Mkt cap ! $1.689B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $12.03M | 8.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 10946 | $1.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 100835 | 8 |
View Market Depth
| Last trade - 13.01pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |